Navigation Links
Mayo Clinic Proceedings January Tip Sheet
Date:1/18/2008

ROCHESTER, Minn., Jan. 18 /PRNewswire-USNewswire/ -- Featured articles from the January issue of Mayo Clinic Proceedings include the effects of antioxidant supplements on cancer, guidelines for workplace drug screening and the safety and effectiveness of nasal spray flu vaccine.

Mayo Researchers Examine the Effect of Antioxidant Supplements on Cancer

Do antioxidant supplements reduce the risk of cancer and deaths related to cancer? That's a question answered by Mayo researchers in an article in the January issue of Mayo Clinic Proceedings. While some trials have suggested that antioxidants have beneficial effects, results from other trials have been negative. It has been unclear which antioxidant compounts are more beneficial (or more harmful), and how individual antioxidants affect target organs and specific patient populations. To examine these issues, Mayo researchers conducted a systematic review on the topic.

"Systematic reviews can provide reliable summaries of the research, and help understand why different studies give different results," says Victor Montori, M.D., senior author on the study and lead for Mayo Clinic's Knowledge and Encounter Research (KER) unit. For the study, two authors reviewed all randomized trials on antioxidants for cancer prevention(1968-2005) and identified 12 clinical trials with a total eligible population of 104,196. The review yielded a number of interesting findings including:

-- Overall, antioxidant supplementation did not reduce the risk of cancer.

-- Beta carotene supplementation was actually found to increase the risk of smoking-related cancers, as well as cancer mortality, and thus should be avoided, especially by tobacco users.

-- Vitamin E appeared to have no beneficial or harmful effects.

-- Selenium supplementation was found to lower the risk of cancer in men (not in women), but the number of trials were few and further research is required. A large t
'/>"/>

SOURCE Mayo Clinic Proceedings
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-2168
2. FDA Grants Approval to Extend U.S. Enrollment and Clinical Trial
3. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
4. CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)
5. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
6. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
7. Cleveland Clinic to Lead First Head-to-Head Comparison of the Two Most Potent Statins
8. RADIESSE More Effective Than Restylane As Reported In a 60-Patient Clinical Trial
9. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
10. OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) has Lower MACE Rate than TAXUS(R) and CYPHER(R) Stents in Clinical Trial
11. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... DUBLIN , Sept. 2, 2015 Research ... of the "Inhaled Drug Delivery (London, UK - ... This Inhaled Drug Delivery meeting will cover industry ... and much more. The Co-Chairmen are Dr Steven ... , Senior Director, Mylan. Companies participating ...
(Date:9/2/2015)... , Sept. 2, 2015  Seeger Weiss LLP ... bellwether trial will commence October 13, 2015. ... the 510K fast-track approval program, Zimmer NexGen knee implant ... only requires that companies provide evidence that the product ... in order to gain permissions. In ...
(Date:9/2/2015)... -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today ... Neurocrine Biosciences, will be presenting at the Baird 2015 ... . The live presentation takes place on ... presentation will be webcast and may be accessed on ... Listeners are encouraged to visit the website approximately ...
Breaking Medicine Technology:Seeger Weiss LLP Reports That Zimmer NexGen Knee MDL Bellwether Trial Date Set For October 13, 2015 2
... First-in-Class Biologic Treatment Option Now Available for ... Use in Pediatric Patients with JIA(1,2) -, PRINCETON, ... ) today announced that the U.S. Food and Drug,Administration (FDA) ... patients six years and older with moderately to,severely active polyarticular ...
... Model Created Using Piecewise Smooth Subdivision Surface Provides Both ... of Fallot Patients, SEATTLE, April 8, 2008 ... and volumetric insights,that help cardiologists diagnose and treat patients ... in the American Journal,Cardiology (2008; Vol. 101, Issue 1, ...
Cached Medicine Technology:U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 2U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 3U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 4U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 5U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 6U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 7U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 8U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 9U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 10Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology 2Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology 3
(Date:9/3/2015)... ... ... types of people who have a hard time gaining weight , it seems that ... those that have a fast metabolism. In order to help those people who have a ... slowing down metabolism. , The first thing to do is to space out meals. When ...
(Date:9/3/2015)... ... , ... James Earl Jones will be hosting an upcoming VOICES IN AMERICA ... will introduce a segment that discusses why it is important for the workplace to ... fostered in any working environment. , Employers are out billions of dollars year after ...
(Date:9/3/2015)... ... September 03, 2015 , ... The partnership will ... and technical support services to promote LodonalTM in Nigeria. The distribution will become ... efficacy and safety of the product. , Managing Director, Fidson Healthcare Plc, Dr ...
(Date:9/2/2015)... ... , ... Leah Binder, MA, MGA, president and CEO of ... will offer the keynote address at the upcoming meeting of the ACO and ... Florida, at the Innisbrook Resort and Golf Club. For an agenda and registration, ...
(Date:9/2/2015)... (PRWEB) , ... September 03, 2015 , ... ... nominations to determine who among America’s policymakers, public servants, activists, corporate executives, entrepreneurs, ... nation’s health care. This year, that process led the magazine to tap the ...
Breaking Medicine News(10 mins):Health News:CB-1 Weight Gainer Gives Three Tips for Slowing Down Metabolism 2Health News:CB-1 Weight Gainer Gives Three Tips for Slowing Down Metabolism 3Health News:James Earl Jones Hosts a New "Voices In America" Piece on Making the Workplace Healthier 2Health News:Fidson Partners US Firms on New Product Marketing 2Health News:Fidson Partners US Firms on New Product Marketing 3Health News:Fidson Partners US Firms on New Product Marketing 4Health News:ACO Coalition Meeting to Feature Leapfrog’s Leah Binder 2Health News:ACO Coalition Meeting to Feature Leapfrog’s Leah Binder 3Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 3
... , , Gail McG ... Climate , , WASHINGTON, July 13 ... featured speaker at a National Press Club Luncheon on Tuesday, July 21, 2009. ... , , (Logo: http://www.newscom.com/cgi-bin/prnh/20090108/RedCrossLOGO ) , ...
... MINNEAPOLIS, July 13 Nonin Medical, Inc., ... clearance for its Model 7600 Regional Oximetry System. Introduced in ... in Milan, Italy, the innovative Model 7600 offers real-time monitoring ... , , Utilizing next-generation near-infrared ...
... WASHINGTON, July 13 The Health Coalition on Liability ... legislative proposals for medical liability reform that they will push ... consideration by Congress. , , ... system in order to provide fair and timely compensation to ...
... 17-year-olds without prescription, company says , MONDAY, July 13 (HealthDay ... contraceptive has been approved by the U.S. Food and Drug ... , The new Plan B One-Step will be available at ... The FDA also said it expanded over-the-counter access to Plan ...
... still transmit virus, but disease odds fall by 30 percent, ... who use condoms regularly can reduce their risk of getting ... The herpes simplex virus 2 (HSV-2) causes genital herpes, which ... that regular condom use reduces the spread of HIV and ...
... Leading hearing system ... their work on Hear the World, a global initiative to raise awareness about the importance ... ... the International Stevie Award for Communications Team of the Year for their work on Hear ...
Cached Medicine News:Health News:American Red Cross President to Address National Press Club Luncheon 2Health News:Nonin Medical Announces FDA Clearance for its Next-Generation Regional Oximetry System 2Health News:Health Coalition Sends Legislative Proposals for Medical Liability Reform to Congress 2Health News:Condoms May Reduce Herpes Risk 2Health News:Condoms May Reduce Herpes Risk 3Health News:Phonak and Hear the World Wins International Stevie Award in Sixth Annual International Business Awards 2Health News:Phonak and Hear the World Wins International Stevie Award in Sixth Annual International Business Awards 3
Aplicare's Prep Pads offer convenience, low cost, ease of use. The medium size is appropriate for most applications. Each package is terminally sterilized, ensuring the safest possible product for th...
IV Prep Swab Sticks are effective, easy to apply, dries quickly and reduces bacterial contaminations. They are ideal for preparation of the skin prior to a ventipuncture or injection....
... Plus Sterile Isopropyl Alcohol ... primarily used as a ... administering injections. They are ... AAMI/ANSI/ISO 11137 standards to ...
... Aplicare's Saturated Swabsticks ... open, single-use foil-laminated pouches. ... is saturated with precisely ... solution. Each package is ...
Medicine Products: